Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes

Article Title: Frailty and Circulating Markers of Inflammation in HIV+ and HIV− Men in the Multicenter AIDS Cohort Study

doi: 10.1097/qai.0000000000001261

Figure Lengend Snippet: FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each biomarker, adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.

Article Snippet: Serum levels of soluble (s) CD14, sCD27, sgp130, sIL6 receptor (sIL-6R), sIL-2 receptor-a (sCD25), and sTNF receptor-2 (sTNFR2), plus a cytokine known as B-cellactivating factor or B-lymphocyte stimulator (BAFF/BLyS), and the chemokine CXCL13 (B-lymphocyte chemoattractant/ B-cell-attracting chemokine 1; BLC/BCA1) were measured in one custom-designed multiplexed assay panel (Human Biomarker Custom Premix Kit A, R & D Systems, Minneapolis, MN) per manufacturer’s directions at the University of California, Los Angeles, using a Bio-Plex 200 Luminex instrument and Bio-Plex analysis software (Bio-Rad, Hercules, CA).

Techniques: Biomarker Discovery, Infection, Comparison

Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes

Article Title: Frailty and Circulating Markers of Inflammation in HIV+ and HIV− Men in the Multicenter AIDS Cohort Study

doi: 10.1097/qai.0000000000001261

Figure Lengend Snippet: FIGURE 3. Relative percentile estimates (d) and 95% confidence limits (error bars) of the estimates for the frail HIV+ men compared with nonfrail HIV+ men. Data were generated using generalized gamma regression models for each biomarker adjusted for age, race, study sites, and education (left bars with d, model 1) and further adjusted for BMI, current smoking, presence of depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer (right bars with d, model 2). Relative percentile differences between the frail and nonfrail HIV+ men that were significantly different at P # 0.002 are indicated by #; those that were significantly different at 0.002 # P #0.05 are those for which the 95% confidence intervals do not include 1.0.

Article Snippet: Serum levels of soluble (s) CD14, sCD27, sgp130, sIL6 receptor (sIL-6R), sIL-2 receptor-a (sCD25), and sTNF receptor-2 (sTNFR2), plus a cytokine known as B-cellactivating factor or B-lymphocyte stimulator (BAFF/BLyS), and the chemokine CXCL13 (B-lymphocyte chemoattractant/ B-cell-attracting chemokine 1; BLC/BCA1) were measured in one custom-designed multiplexed assay panel (Human Biomarker Custom Premix Kit A, R & D Systems, Minneapolis, MN) per manufacturer’s directions at the University of California, Los Angeles, using a Bio-Plex 200 Luminex instrument and Bio-Plex analysis software (Bio-Rad, Hercules, CA).

Techniques: Generated, Biomarker Discovery, Infection

Journal: eLife

Article Title: A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids

doi: 10.7554/eLife.52904

Figure Lengend Snippet:

Article Snippet: Commercial assay or kit , Biomark 48.48integrated fluidic circuit Delta Gene assay , Fluidigm , Cat#:101–0348 , Complete bundle for 10 assays.

Techniques: Sequencing, Gene Assay, Viability Assay, Catecholamine ELISA, Software

Journal: Nutrients

Article Title: Postbiotics from Lacticaseibacillus rhamnosus IOB820 Combat Obesity in HFD Mice by Modulating Gut Microbiota and Enhancing SCFA Production

doi: 10.3390/nu17223525

Figure Lengend Snippet: Modulation of Serum Lipid Profiles and Hepatic Metabolic Markers by L . rhamnosus IOB820 and Postbiotics in HFD Mice. ( a – d ) Quantification of serum lipid parameters: TC, TG, LDL-C, and HDL-C; ( e – g ) Analysis of hepatic metabolic biomarkers: ALP, AST, and CPT-1 expression. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. HFD group, n = 6.

Article Snippet: Serum samples and mechanically ground liver tissue homogenates were analyzed for the quantitative determination of the following biomarkers: low-density lipoprotein cholesterol (LDL-C, A113-2-1, Nanjing Jiancheng, Nanjing, China), high-density lipoprotein cholesterol (HDL-C, A112-2-1, Nanjing Jiancheng), total cholesterol (TC, A111-1-1, Nanjing Jiancheng), triglycerides (TG, A110-1-1, Nanjing Jiancheng), tumor necrosis factor-α (TNF-α, ZC-39024, Shanghai ZCIBIO, Shanghai, China), interleukin-10 (IL-10, ZC-37962, Shanghai ZCIBIO), interleukin-6 (IL-6, ZC-37988, Shanghai ZCIBIO), interleukin-1β (IL-1β, ZC-37974, Shanghai ZCIBIO), aspartate aminotransferase (AST, ZC-38728, Shanghai ZCIBIO), and alkaline phosphatase (ALP, ZC-33964, Shanghai ZCIBIO).

Techniques: Expressing